Core Viewpoint - Hims & Hers Health, Inc. is facing two securities class action lawsuits due to allegations of deceptive marketing practices and failure to disclose critical information, particularly related to its collaboration with Novo Nordisk and the weight loss drug Wegovy® [1][4][5] Group 1: Lawsuits and Allegations - Two class action lawsuits were filed against Hims & Hers Health, Inc. and certain executives, representing investors who acquired securities between April 29, 2025, and June 23, 2025 [1] - The lawsuits allege that Hims & Hers made false and misleading statements and engaged in deceptive promotion of knockoff versions of Wegovy®, which jeopardized patient safety and led to the termination of its collaboration with Novo Nordisk [4][5] - The lawsuits were prompted by Novo Nordisk's announcement on June 23, 2025, that it terminated its collaboration due to concerns over Hims & Hers' illegal practices and deceptive marketing [2][5] Group 2: Investor Impact and Actions - Following the termination of the collaboration, Hims & Hers shares experienced a significant decline of 30% [2] - Hagens Berman, a national shareholders rights firm, is investigating the claims and encourages affected investors to submit their losses [3][6] - The lead plaintiff deadline for the lawsuits is set for August 25, 2025 [3] Group 3: Whistleblower Information - Individuals with non-public information regarding Hims & Hers are encouraged to assist in the investigation or consider the SEC Whistleblower program, which offers rewards for original information leading to successful recoveries [7]

RT CoinDesk (@CoinDesk)NOW: 🇺🇸 "[Ripple was] the first leading U.S. company to be sued by the SEC," @bgarlinghouse says before the Senate."Fortunately, after four years of a hard fought legal battle, we prevailed." https://t.co/xGocFmZWNp ...

Group 1 - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating Core Scientific, Inc. related to its sale to CoreWeave, Inc. [1] - Upon completion of the proposed transaction, each outstanding share of Core Scientific common stock will be converted into the right to receive 0.1235 shares of CoreWeave Class A common stock [1] - Core Scientific shareholders will own less than 10% of the combined company after the transaction [1] Group 2 - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1] - The firm is headquartered in the Empire State Building, New York City, and has a successful track record in trial and appellate courts, including the U.S. Supreme Court [2]

Core Insights - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating PB Bankshares Inc. in relation to its proposed sale to Norwood Financial Corp. [1] - The transaction offers PB Bankshares' shareholders the choice of receiving either 0.7850 shares of Norwood common stock or $19.75 in cash for each common share they own, with a proration clause ensuring that 80% of the total consideration is paid in Norwood stock [1] Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has a successful track record in recovering millions for shareholders [1] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2] Transaction Details - The proposed sale of PB Bankshares to Norwood Financial Corp. includes an option for shareholders to elect their preferred form of compensation, either stock or cash [1] - The proration mechanism is designed to ensure that a significant majority (80%) of the transaction consideration is distributed in the form of Norwood common stock [1]

NOW: 🇺🇸 "[Ripple was] the first leading U.S. company to be sued by the SEC," @bgarlinghouse says before the Senate."Fortunately, after four years of a hard fought legal battle, we prevailed." https://t.co/xGocFmZWNp ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its gene therapy treatment, ELEVIDYS, during the specified Class Period from June 22, 2023, to June 24, 2025 [1][2]. Group 1: Allegations Against Sarepta - The lawsuit claims that Sarepta made false or misleading statements about the safety risks associated with its gene therapy treatment, ELEVIDYS [2]. - It is alleged that the trial protocols for ELEVIDYS failed to identify severe side effects, which could lead to regulatory scrutiny and halt recruitment and dosing in ongoing trials [2]. - The severity of adverse events from ELEVIDYS treatment is said to have been downplayed, resulting in materially misleading statements from the company [2]. Group 2: Lead Plaintiff Process - Investors in Sarepta have until August 25, 2025, to apply to be appointed as lead plaintiffs, representing the interests of the class in the litigation [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial stake in the case [3]. - Participation as a lead plaintiff does not affect the ability of other investors to share in any potential recovery from the lawsuit [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is the law firm handling the class action and has a reputation for prosecuting class actions and recovering significant amounts for victims of corporate misconduct [4]. - The firm encourages affected investors to reach out for more information regarding the lawsuit [4].

Core Points - A shareholder class action lawsuit has been filed against Red Cat Holdings, Inc. alleging that the company made materially false and misleading statements regarding its production capacity and the value of the SRR Contract [1] - The lawsuit claims that the defendants overstated the production capacity of the Salt Lake City Facility and the overall value of the SRR Contract, leading to misleading public statements [1] Legal Information - Shareholders who purchased Red Cat shares between March 18, 2022, and January 15, 2025, and suffered significant losses are encouraged to discuss their legal rights with the law firm Holzer & Holzer [2] - The deadline to request to be appointed as lead plaintiff in the case is July 22, 2025 [3]

Group 1 - The Rosen Law Firm is reminding purchasers of Compass Diversified Holdings securities from March 1, 2023, to May 7, 2025, about the lead plaintiff deadline for a securities class action on July 8, 2025 [1] - Investors who purchased Compass securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6] Group 2 - The lawsuit alleges that during the class period, Compass' subsidiary, Lugano Holdings, Inc., had unrecorded financing arrangements and irregularities in its financial statements, which affected the reliability of Compass' overall financial statements [5] - The lawsuit claims that Compass failed to maintain adequate internal controls related to its financial statements, leading to materially false and misleading public statements [5]

ATLANTA, Ga., July 08, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against iRobot Corporation (“iRobot” or the “Company”) (NASDAQ: IRBT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information about iRobot’s business, operations, and prospects, including allegations that: (i) iRobot overstated the extent to which the Restructuring Plan would help the Company maintain stability after the term ...

Core Viewpoint - Krispy Kreme, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its partnership with McDonald's and declining product demand, which has resulted in significant financial losses for investors [1][4][5]. Group 1: Company Overview - Krispy Kreme manufactures and sells doughnuts and has been expanding its partnership with McDonald's since October 2022, starting with a small-scale test in Louisville, Kentucky [3]. - The partnership was announced to expand nationwide in the second half of 2024 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that during the class period, Krispy Kreme failed to disclose a significant decline in demand for its products at McDonald's locations, which negatively impacted average sales [4]. - It is alleged that the partnership with McDonald's was not profitable and posed risks to its continuation, leading to a suspension of further expansion into new locations [4]. - On May 8, 2025, Krispy Kreme reported a net revenue of $375.2 million, a 15.3% year-over-year decline, and a net loss of $33.4 million, compared to a $6.7 million loss the previous year [5]. - Following the financial report and reassessment of the rollout schedule with McDonald's, Krispy Kreme's stock price fell nearly 25% [5].